Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
134 hedge funds and large institutions have $1.39B invested in Blueprint Medicines in 2017 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 50 increasing their positions, 27 reducing their positions, and 9 closing their positions.
400% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 9
90% more capital invested
Capital invested by funds: $730M → $1.39B (+$657M)
85% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 27
47% more call options, than puts
Call options by funds: $2.84M | Put options by funds: $1.94M
30% more funds holding
Funds holding: 103 → 134 (+31)
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
23.39% more ownership
Funds ownership: 80.56% → 103.96% (+23%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$91.3M |
| 2 |
BlackRock
New York
|
+$73.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$45.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$33.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$41.3M |
| 2 |
DM
Deerfield Management
New York
|
-$17.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.66M |
| 4 |
SH
Sandia Holdings
Greenwich,
Connecticut
|
-$7.47M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$6.08M |
BPMC Hedge Fund Activity: Q1 2017 in Review
134 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2017, worth a combined $1.39B — up 90% from $730M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new BPMC positions and 9 closed out — a net gain of 36 holders — while 50 added to existing stakes and 27 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $91.3M. The largest seller was BVF Inc, cutting an estimated $41.3M.
- 134 institutional investors held Blueprint Medicines (BPMC) as of Q1 2017, up from 103 in Q4 2016.
- Funds reported $1.39B of Blueprint Medicines stock for Q1 2017, up 90% quarter-over-quarter.
- 45 funds opened new Blueprint Medicines positions in Q1 2017 and 9 closed out, a net change of +36 holders.
- The largest Blueprint Medicines buyer in Q1 2017 was Wellington Management Group, an estimated $91.3M added.
- The largest Blueprint Medicines seller in Q1 2017 was BVF Inc, an estimated $41.3M sold.
Based on aggregated 13F filings for Q1 2017.